Reviewed by Stacy Pleasant, MSN, FNP-C, APRN. Educational content. This article does not diagnose any condition and does not recommend any treatment. Whether any therapy is appropriate for you is a decision for a licensed clinician who has assessed you in full.
Type "benefits of testosterone for women" into a search engine and the first page is a wall of lists: more energy, better mood, sharper thinking, stronger muscles, denser bones, easier weight loss, a better sex life. Nearly every one of those lists sits on a page that sells testosterone.
So this article does something different. It takes the nine benefits most often claimed and grades each one against what randomized controlled trials have actually found. The main source is the largest body of evidence that exists on the question: a 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology that pooled 36 randomized trials involving 8,480 women, and the Global Consensus Position Statement that eleven medical societies built on it the same year. Where newer trials or guidance add something, they are cited.
The grades are simple. Supported means randomized trials found a benefit. Not supported means trials looked and did not find one. Unknown means the trials have not been done or are too small to say.
If you want the longer story of what testosterone does in a woman's body, how it changes with age and how it should be measured, the testosterone for women pillar covers it. This article is only about the claims.
Claim 1: Testosterone improves sexual desire and satisfaction
Grade: Supported, for one group.
This is the one claim the evidence carries. In the pooled trials, postmenopausal women with hypoactive sexual desire disorder, meaning persistently low desire that causes personal distress after other causes have been assessed, reported improvements in desire, arousal, orgasm, pleasure and sexual self-image, and a reduction in sexual distress, compared with placebo. The size of the effect was about one additional satisfying sexual event per month.
Two qualifications matter. The benefit was shown in postmenopausal women; the trials in premenopausal women were too few and too small for the consensus panel to draw a conclusion. And the effect is modest. One more satisfying event a month is a real and measurable change for a woman who is distressed by low desire. It is not the transformation that the marketing describes.
The 2021 clinical practice guideline from the International Society for the Study of Women's Sexual Health reached the same position, and so did the British Menopause Society's May 2026 tool for clinicians.
Claim 2: Testosterone gives women more energy
Grade: Not supported.
Energy and fatigue are the benefits women most often say they are looking for, and they are the ones the trials least support. The 2019 consensus statement found insufficient evidence for any effect on general wellbeing, and the British Menopause Society's 2026 clinician tool states that trials to date have not demonstrated benefit for energy. At The Menopause Society's 2025 annual meeting, Professor Susan Davis, the lead author of the consensus statement, summarized the trial record on fatigue and vitality as showing no proven benefit, and said plainly that testosterone "is not the silver bullet; it is not the missing hormone."
Why do so many women say they feel more energetic on it? Three reasons the trials can separate and a survey cannot: placebo response is large for fatigue; women who feel nothing tend to stop and drop out of the data; and energy often improves when sexual function and relationship stress improve. Randomized trials control for all three. Testimonials control for none.
Claim 3: Testosterone lifts mood and reduces anxiety
Grade: Not supported.
The pooled trials found no effect on psychological wellbeing or depressive mood. Professor Davis described the trial results for mood as "underwhelming," with no improvement in anxiety or psychological wellbeing. Low mood in midlife has well-documented drivers that a blood panel and a clinical history can find: thyroid disease, iron deficiency, poor sleep, the estrogen swings of perimenopause, and depression itself, which deserves its own assessment rather than a hormone.
Claim 4: Testosterone sharpens memory and clears brain fog
Grade: Not supported.
The meta-analysis found no benefit on cognitive measures. Reviewing the field at the 2025 meeting, Professor Davis described the cognition findings as inconsistent and inconclusive, with one small study showing a subtle improvement in immediate recall and nothing that has held up at scale. A trial designed to test quality-of-life and cognitive outcomes properly is still running. Until it reports, "brain fog" is a symptom with a long differential list, and testosterone is not on the evidence-based part of it. The fatigue and brain fog page covers what that differential looks like in practice.
Claim 5: Testosterone builds muscle and strength
Grade: Not supported at normal female levels.
This claim borrows from men, where testosterone has clear effects on lean mass. In women at physiological levels, the pooled trials found no improvement in lean body mass or muscle strength. A 2025 randomized trial in JAMA Network Open tested the idea directly in 129 women with a mean age of 79 recovering from hip fracture: adding a testosterone gel to a supervised exercise program produced no difference in six-minute walking distance, lean mass or strength compared with exercise plus placebo, and the testosterone group recorded more serious adverse events. The exercise, on the other hand, worked in both groups. If strength is the goal, the intervention with the evidence is resistance training.
Claim 6: Testosterone protects bone
Grade: Unknown, leaning not supported.
Bone density is where a plausible mechanism meets an absent result. Testosterone receptors are present in bone, and observational data show weak correlations between androgen levels and bone density. But the randomized trials found no effect on bone mineral density, and no trial has measured the outcome that matters, which is fractures. The consensus panel listed bone health among the outcomes with insufficient evidence. For bone, the interventions with trial evidence are different ones, and a woman worried about her bones should be having that conversation, not this one.
Claim 7: Testosterone helps women lose weight
Grade: Not supported.
The trials found no improvement in body composition. There is no randomized evidence that testosterone produces weight loss in women, and the retrospective surveys that report it cannot separate the hormone from the diet, training and attention that come with joining a hormone program. Weight regulation in midlife runs through insulin, thyroid, sleep, muscle mass and, in perimenopause, estrogen, all of which can be measured.
Claim 8: Testosterone is good for the heart and metabolism
Grade: Unknown; route matters for cholesterol.
Short-term trial data found no adverse effect on blood pressure, glucose or insulin. On cholesterol the route made the difference: oral testosterone was associated with unfavorable lipid changes in the trials, which is why the consensus does not recommend oral products, while non-oral products did not show that effect in the short term. Whether testosterone changes the rate of heart attacks or strokes in women over years is unknown, because no trial has been large enough or long enough to measure it, and women at higher cardiovascular risk were excluded from the trials that exist.
A 2026 retrospective study of 332 women from a single telehealth hormone service, published in the Journal of Personalized Medicine, reported lower triglycerides and large self-reported gains in energy, mood and quality of life. Its own limitations section explains why it cannot overturn the trial record: the women were self-selected, those who stopped were absent from the data, symptoms were rated once, after the fact, on an unvalidated survey, and there was no placebo group. That is the pattern behind most "new study shows" headlines on this topic.
Claim 9: Testosterone is safe for women long term
Grade: Unknown.
Within the normal premenopausal range and over trial durations of up to about two years, the pooled data were reassuring: mild increases in acne and facial or body hair, no scalp hair loss, voice change or clitoral enlargement, no increase in mammographic breast density and no breast cancer signal in short-term data. No participant withdrew from the trials over the cosmetic effects.
Beyond two years the record is empty. The consensus panel was explicit that long-term safety, including breast cancer and cardiovascular events over many years, has not been established. And the reassuring data apply only to levels kept within the female range. Pellets and injections, which both the consensus and the ISSWSH guideline recommend against, push levels above that range, cannot be adjusted once given, and carry the risk of effects that do not go away, including voice change and clitoral enlargement. There is still no testosterone product approved by the Food and Drug Administration for women; any use in the United States is off-label.
The scorecard
| Claimed benefit | Grade | Basis |
|---|---|---|
| Sexual desire and satisfaction | Supported, postmenopausal women with distressing low desire | 36 trials, 8,480 women; about one more satisfying sexual event per month |
| Energy | Not supported | No demonstrated benefit in trials; consensus 2019; BMS 2026 |
| Mood and anxiety | Not supported | No effect on wellbeing or depressive mood |
| Memory and brain fog | Not supported | No effect on cognitive measures; a dedicated trial still running |
| Muscle and strength | Not supported at female levels | No change in lean mass or strength; STEP-HI 2025 |
| Bone | Unknown, leaning not supported | No change in bone density; no fracture data |
| Weight loss | Not supported | No change in body composition |
| Heart and metabolism | Unknown; oral products worsen lipids | Short-term neutral; no long-term outcome trial |
| Long-term safety | Unknown | Reassuring to about two years at female levels; nothing beyond |
One supported claim out of nine, in one group, at a modest size. That is the honest answer to the search.
What this means if you are the one searching
The symptoms behind this search are real. Low desire, flat energy, low mood, foggy thinking, softer muscle, a thicker middle: every one of them is common in women from the late thirties on, and every one has causes that a properly built blood panel can see. Thyroid function, iron and ferritin, fasting insulin and glucose, inflammation, vitamin D, estradiol, DHEA-S, SHBG, and testosterone itself measured by the right method, which for women means mass spectrometry rather than the immunoassay most labs run by default.
Start there. The guidelines are unanimous that no blood level of testosterone defines a deficiency in women or predicts those symptoms, so the useful question is not "is my testosterone low" but "what is the whole picture saying, and what has already been ruled out." For a woman in perimenopause or menopause, that picture usually turns first on estrogen and the symptoms that come with its swings; the women's hormone health page explains how 1836 approaches that assessment in Houston.
The Focused Assessment covers core metabolic testing, including fasting insulin, with named Labcorp tests, a mobile blood draw at your home, office or another location you choose, a results review with your clinician by video and written next steps. For hormone questions, the Comprehensive Assessment adds hormone, thyroid and nutrient testing, including total and free testosterone with SHBG and albumin, sensitive estradiol, DHEA-S, TSH with free T4 and free T3, vitamin D and cortisol; compare the two. Your clinician may add or remove tests based on your history. That is the assessment the evidence actually calls for.
Frequently asked questions
What are the proven benefits of testosterone for women? One: improved sexual desire, arousal, orgasm and satisfaction, with less sexual distress, in postmenopausal women diagnosed with hypoactive sexual desire disorder after other causes have been assessed. That is the only indication the 2019 Global Consensus Position Statement found evidence for. The effect in the pooled trials was about one additional satisfying sexual event per month.
Does testosterone give women more energy? Randomized trials have not shown it. The 2019 consensus found insufficient evidence for wellbeing, and the British Menopause Society's 2026 guidance states that trials to date have not demonstrated benefit for energy. Reports of more energy come mainly from surveys of women already on treatment, which cannot separate the hormone from placebo response and drop-out.
Does testosterone help women build muscle or lose weight? At normal female levels, no. The pooled trials found no change in lean mass, muscle strength or body composition, and a 2025 randomized trial in older women found that adding testosterone to a supervised exercise program added nothing to walking distance, lean mass or strength over exercise alone.
Is testosterone safe for women? Short-term trial data at levels within the normal female range were reassuring, with mild acne and hair growth as the main effects and no breast cancer signal over about two years. Long-term safety has not been established, no product is FDA-approved for women; the guidelines recommend against pellets, injections and compounded products because they produce levels above the female range or lack safety data.
Reviewed by Stacy Pleasant, MSN, FNP-C, APRN. This article is educational and is not medical advice, a diagnosis, or a treatment recommendation. Lab results should be interpreted with a licensed clinician who knows your history.
Want the whole picture read by a clinician, not one number read by a sales page? Book your assessment: the Focused Assessment covers core metabolic testing, and the Comprehensive Assessment adds hormone, thyroid and nutrient testing, each with a mobile blood draw at your home, office or another location you choose.
Sources
Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. The Lancet Diabetes and Endocrinology, 2019. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30189-5/abstract
Monash University. Large study shows beneficial role of testosterone for postmenopausal women. https://www.monash.edu/medicine/news/latest/2019-articles/large-study-shows-beneficial-role-of-testosterone-for-postmenopausal-women
Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology and Metabolism, 2019. https://academic.oup.com/jcem/article/104/10/4660/5556103
Parish SJ, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine, 2021. https://www.isswsh.org/images/PDF/jsm_18_5_849.pdf
British Menopause Society. Tool for Clinicians: Testosterone replacement in menopause, May 2026. https://thebms.org.uk/wp-content/uploads/2026/05/08-NEW-BMS-TfC-Testosterone-replacement-in-menopause-MAY2026-A.pdf
American Journal of Managed Care. Jury Still Out on Testosterone Benefit to Menopause, October 31, 2025. https://www.ajmc.com/view/jury-still-out-on-testosterone-benefit-to-menopause
STEP-HI trial investigators. Combining Exercise Training and Testosterone Therapy in Older Women After Hip Fracture: The STEP-HI Randomized Clinical Trial. JAMA Network Open, May 2025. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2834116
Testosterone Replacement Therapy in Women Is Associated with Improved Symptom Burden and Favorable Biomarker Changes: A Retrospective Observational Study. Journal of Personalized Medicine, 2026. https://www.mdpi.com/2075-4426/16/5/231
US Department of Veterans Affairs Pharmacy Benefits Management. Transdermal Testosterone (Off-Label) for Hypoactive Sexual Desire Disorder: Clinical Summary, March 2025. https://www.va.gov/formularyadvisor/DOC_PDF/CRE_Testosterone_HSDD_Clinical_Summary_Mar_2025.pdf
Wierman ME, et al. Androgen Therapy in Women: A Reappraisal. An Endocrine Society Clinical Practice Guideline, 2014. https://www.endocrine.org/clinical-practice-guidelines/androgen-therapy-in-women
